A Federal district judge here has dismissed Barr Laboratories' claim that DuPont Pharmaceuticals violated Federal antitrust law in publicly advocating before state legislatures patients' right to know which brand of the anticoagulant medication, warfarin, they have been prescribed.
Any injuries actually suffered by class plaintiffs are too remote to justify antitrust standing.
Petition for Stay was anything other than a successful attempt to secure more stringent bioequivalency standards for generic warfarin sodium drugs. This is the third consecutive court ruling confirming DuPont Pharmaceuticals' First Amendment right to freely engage in this important patient safety debate. The company said it was pleased the court dismissed the Barr claim and the three class actions at the earliest possible time in the proceedings. Although certain of Barr's claims were not dismissed at this early stage, the company said it is confident that it will ultimately prevail against these other claims as well. An NTI drug is one whose dosage must be carefully administered and monitored because there is very little difference in what makes an effective dose and what could be a toxic dose.